{"schema_version":"secwatch.filing_event.v1","accession":"0001753926-24-001872","form_type":"8-K","ticker":"VANI","cik":"0001266806","company_name":"Vivani Medical, Inc.","filed_at":"2024-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.930747+00:00","generated_at":"2026-05-30T00:49:34.345008+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Vivani Medical Q3 net loss $6.0M; $5M equity financing; GLP-1 implant study approved in Australia","bullets":["Net loss $6.0M for Q3 2024 vs $6.8M YoY; cash $21.0M as of Sept 30, 2024.","Regulatory approval in Australia for LIBERATE-1 Phase 1 trial of GLP-1 (exenatide) implant in obese/overweight patients.","Private sale of 3.97M shares at $1.26/share to a director for $5.0M gross proceeds, extending runway into late 2025.","Preclinical data: 82% sham-implant adjusted liver fat reduction and 20% weight loss comparable to semaglutide.","R&D expense $4.2M (-5% YoY); G&A $2.1M (-22% YoY); operating expenses decreased $0.8M."],"urls":{"canonical":"https://secwatch.observer/filing/0001753926-24-001872","json":"https://secwatch.observer/filing/0001753926-24-001872.json","markdown":"https://secwatch.observer/filing/0001753926-24-001872.md","text":"https://secwatch.observer/filing/0001753926-24-001872.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1266806/000175392624001872/0001753926-24-001872-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1266806/000175392624001872/vani-20241113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:49:34.345008+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}